argenx initiates Phase II trial of ARGX-113 to treat pemphigus vulgaris

Belgium-based biotechnology firm argenx has initiated a Phase II clinical trial of its investigational agent, ARGX-113, to treat patients with pemphigus vulgaris (PV).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news